Kairos Pharma Reports $1.262 Million Net Loss in Q1 2025, No Revenue Generated

Kairos Pharma, Ltd. reported its financial results for the first quarter of 2025, revealing a net loss of $1.262 million, a significant increase from the $323,000 loss recorded in the same period of 2024. The company did not generate any revenue during this quarter, consistent with its ongoing status as a clinical-stage biopharmaceutical firm focused on developing immunotherapy and cell therapy treatments for cancer. Total operating expenses for the quarter amounted to $1.266 million, up from $287,000 in the prior year, primarily driven by increased research and development costs associated with ongoing clinical trials.

The company's cash and cash equivalents rose to $3.616 million as of March 31, 2025, compared to $1.272 million at the end of 2024. This increase was bolstered by a private financing round in January 2025, which yielded net proceeds of $3.145 million. Shareholders' equity also saw a substantial increase, reaching $7.132 million, up from $4.776 million at the end of the previous fiscal year. The company’s total assets increased to $7.937 million, reflecting a strategic focus on enhancing its financial position to support ongoing operations.

In terms of operational developments, Kairos Pharma has been actively engaged in clinical trials, particularly for its product candidates ENV 105 and KROS 201. The company is currently conducting Phase 1 and Phase 2 trials for ENV 105, which targets prostate cancer, and a Phase 1 trial for KROS 201. The increase in research and development expenses, which rose to $493,000 from $165,000 year-over-year, reflects the company's commitment to advancing these clinical programs. Additionally, the company has entered into various vendor agreements to support its clinical research efforts, including contracts with Prevail Infoworks and PreCheck Health Services.

Looking ahead, Kairos Pharma anticipates continued operating losses as it progresses through its clinical development phases. The company expects its current cash reserves to sustain operations for at least the next 12 months, but it will require additional funding to support its growth strategy and operational needs. The management has indicated that future financing may involve equity or debt offerings, and the company remains focused on securing partnerships and collaborations to enhance its financial stability and operational capabilities. The outlook remains contingent on the successful advancement of its product candidates through clinical trials and obtaining necessary regulatory approvals.